NLRP3 gene therapy (Vesigen Therapeutics)

N/A

Report date: 2025/08/13 16:51:10

Base Information

Drug NameNLRP3 gene therapy (Vesigen Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 modulators
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsAcute Kidney Injury
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVesigen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVesigen Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAcute Kidney Injury
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A